Evidence map›Paper›PMID 32309036›Full record

ReviewNeurology. Clinical practice2020

Immediate reactions with glatiramer acetate: Diagnosis of allergy and desensitization protocols.

Guadalupe Marco-Martín, Pilar Tornero, Alicia Prieto, Alejandro La Rotta, Teresa Herrero, Maria Luisa Baeza

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Neurology. Clinical practice, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Guadalupe Marco-MartínAllergy Department Hospital General Universitario Gregorio Marañón (GM-M, PT, AP, ALR, TH, MLB); Allergy Department (GM-M), Hospital Universitario Infanta Sofía, Madrid; Allergy Department (ALR), Policlínica Miramar, Palma de Mallorca; Biomedical Research Network on Rare Diseases (U761 CIBERER) (MLB), Instituto de Salud Carlos III; and Institute for Health Research Gregorio Marañón (IIS-GM) (MLB), Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Pilar TorneroAllergy Department Hospital General Universitario Gregorio Marañón (GM-M, PT, AP, ALR, TH, MLB); Allergy Department (GM-M), Hospital Universitario Infanta Sofía, Madrid; Allergy Department (ALR), Policlínica Miramar, Palma de Mallorca; Biomedical Research Network on Rare Diseases (U761 CIBERER) (MLB), Instituto de Salud Carlos III; and Institute for Health Research Gregorio Marañón (IIS-GM) (MLB), Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Alicia PrietoAllergy Department Hospital General Universitario Gregorio Marañón (GM-M, PT, AP, ALR, TH, MLB); Allergy Department (GM-M), Hospital Universitario Infanta Sofía, Madrid; Allergy Department (ALR), Policlínica Miramar, Palma de Mallorca; Biomedical Research Network on Rare Diseases (U761 CIBERER) (MLB), Instituto de Salud Carlos III; and Institute for Health Research Gregorio Marañón (IIS-GM) (MLB), Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Alejandro La RottaAllergy Department Hospital General Universitario Gregorio Marañón (GM-M, PT, AP, ALR, TH, MLB); Allergy Department (GM-M), Hospital Universitario Infanta Sofía, Madrid; Allergy Department (ALR), Policlínica Miramar, Palma de Mallorca; Biomedical Research Network on Rare Diseases (U761 CIBERER) (MLB), Instituto de Salud Carlos III; and Institute for Health Research Gregorio Marañón (IIS-GM) (MLB), Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Teresa HerreroAllergy Department Hospital General Universitario Gregorio Marañón (GM-M, PT, AP, ALR, TH, MLB); Allergy Department (GM-M), Hospital Universitario Infanta Sofía, Madrid; Allergy Department (ALR), Policlínica Miramar, Palma de Mallorca; Biomedical Research Network on Rare Diseases (U761 CIBERER) (MLB), Instituto de Salud Carlos III; and Institute for Health Research Gregorio Marañón (IIS-GM) (MLB), Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Maria Luisa BaezaAllergy Department Hospital General Universitario Gregorio Marañón (GM-M, PT, AP, ALR, TH, MLB); Allergy Department (GM-M), Hospital Universitario Infanta Sofía, Madrid; Allergy Department (ALR), Policlínica Miramar, Palma de Mallorca; Biomedical Research Network on Rare Diseases (U761 CIBERER) (MLB), Instituto de Salud Carlos III; and Institute for Health Research Gregorio Marañón (IIS-GM) (MLB), Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Hospital General Universitario Gregorio Marañón · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewDiverse adverse events have been associated with administration of glatiramer acetate (GA), mainly local reactions at the injection site. Other, less frequent generalized reactions include isolated postinjection reactions and anaphylaxis, which may lead to discontinuation of GA. RECENT

findingsClose collaboration between the allergy and neurology departments is needed to study adverse reactions to GA. The allergy study should include a detailed history and skin prick and intradermal tests with GA and, if possible, determination of specific IgE levels. Furthermore, the implication of other drugs should be ruled out. SUMMARY: An accurate diagnosis of reactions to GA is essential if we are to confirm or rule out allergy to GA. When an allergy diagnosis is confirmed or firmly suspected based on clinical evidence, desensitization protocols are increasingly seen as safe methods for reintroduction of GA.

Identifiers

PMID32309036
PMCPMC7156204
OpenAlexW2971843959

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.